Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8158539 | 0.79 | CDK1 (0.48) | KMT2AALDH1A1HTTMEN1MAPT | |
| SCHEMBL13698953 | 0.75 | ACHE (0.57) | ACHEKMT2AALDH1A1HTTMEN1 | |
| SCHEMBL8508385 | 0.73 | MRGPRX4 (0.49) | KMT2AALDH1A1MEN1MAPTHPGD | |
| SCHEMBL6513151 | 0.72 | CES1 (0.52) | ACHEKMT2AMEN1POLBCASP1 | |
| SCHEMBL10130293 | 0.71 | MEN1 (0.59) | KMT2AALDH1A1HTTMEN1MAPT | |
| SCHEMBL13713255 | 0.71 | GRM5 (0.56) | GRM5HTTMAPTSMN1; SMN2 | |
| SCHEMBL31257881 | 0.70 | ALDH1A1 (0.47) | GRM5KMT2AALDH1A1HTTMEN1 | |
| SCHEMBL1296639 | 0.69 | ACHE (0.64) | ACHEKMT2AALDH1A1HTTMEN1 | |
| SCHEMBL19830158 | 0.69 | MAPT (0.53) | KMT2AALDH1A1HTTMEN1MAPT | |
| SCHEMBL11532947 | 0.68 | HDAC8 (0.60) | ACHEKMT2AALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | ACHE 406/4885GRM5 2168/4885KMT2A 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.